两家独立企业由此诞生
生命科学与诊断 & 分析和企业服务
专注于生命科学和诊断业务的高增长型公司，推动科学家和医疗卫生专业人士的研究、发现和检测，助力打造更健康的世界
我们专注于提供全方位的分析和企业服务解决方案，包括领先的OneSource实验室服务，加速您的科学研究进程
Study targets of metabolic disease in vitro, in vivo and in situ using our biomarker detection kits, imaging systems and target-specific radiolabeled ligands, carbohydrates, lipids, and steroids.
Type 1 and Type 2 diabetes are complex diseases affecting nearly every major bodily organ and impacting the lives of millions of people worldwide.
Understanding the complex cellular and molecular pathways involved in diabetes and translating these findings into new prevention and treatment strategies. Our solutions are helping researchers to:
NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis), are different states of fatty liver disease related pathologies. In these early stages the disease is still reversible, however more progressed pathologies like fibrosis and cirrhosis causing permanent damage to the organ. Thus, it is very important to find new biomarkers and noninvasive tools for early diagnosis of NASH.
NAFLD and NASH is strongly related to fast growing global epidemic of obesity and diabetes and therefore also presumably on the rise.
For a better understanding of the underlying molecular pathways PerkinElmer offers a wide range of ready-to-use assays to monitor biomarkers, phosphoproteins and transcription factors involved in the development and progression of NASH, NAFLD and fibrosis. Our Imaging solutions can also help you to monitor molecular processes or to find diagnostic tools.
